{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:26:50Z","timestamp":1783114010852,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.mayocp.2014.08.012","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T05:15:27Z","timestamp":1414991727000},"page":"1481-1486","source":"Crossref","is-referenced-by-count":15,"title":["Clinical and Histologic Findings in Patients With Uveal Melanomas After Taking Tumor Necrosis Factor-\u03b1 Inhibitors"],"prefix":"10.1016","volume":"89","author":[{"given":"Gena","family":"Damento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen C.","family":"Kavoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Materin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diva R.","family":"Salom\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polly A.","family":"Quiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soranya","family":"Balasubramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose S.","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mayocp.2014.08.012_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrgastro.2009.221","article-title":"Optimizing the safety of biologic therapy for IBD","volume":"7","author":"de Silva","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.mayocp.2014.08.012_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.012_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2007.00138.x","article-title":"TNF-alpha inhibitors","volume":"20","author":"Jackson","year":"2007","journal-title":"Dermatol Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2014.08.012_bib4","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.012_bib5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2133.2005.07094.x","article-title":"Melanomas in renal transplant recipients","volume":"154","author":"Le Mire","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.012_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00002018-200023020-00002","article-title":"Post-transplant malignancy: the role of immunosuppression","volume":"23","author":"Penn","year":"2000","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.mayocp.2014.08.012_bib7","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.012_bib8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.012_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","article-title":"TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility","volume":"11","author":"van Horssen","year":"2006","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.012_bib10","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.sla.0000146147.89667.ed","article-title":"One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases","volume":"240","author":"Gr\u00fcnhagen","year":"2004","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.mayocp.2014.08.012_bib11","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","article-title":"Outcomes following isolated limb infusion for melanoma: a 14-year experience","volume":"15","author":"Kroon","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2014.08.012_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1523-1747.2003.12417.x","article-title":"Tumor necrosis factor alpha increases and alpha-melanocyte-stimulating hormone reduces uveal melanoma invasion through fibronectin","volume":"121","author":"Cant\u00f3n","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.012_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6601257","article-title":"TNF-alpha increases human melanoma cell invasion and migration in\u00a0vitro: the role of proteolytic enzymes","volume":"89","author":"Katerinaki","year":"2003","journal-title":"Br J Cancer"},{"issue":"2, pt 1","key":"10.1016\/j.mayocp.2014.08.012_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","article-title":"Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens","volume":"40","author":"Jensen","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.012_bib15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0190-9622(03)02482-4","article-title":"Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings","volume":"49","author":"Alaibac","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5, suppl","key":"10.1016\/j.mayocp.2014.08.012_bib16","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaad.2003.11.044","article-title":"Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab","volume":"50","author":"Esser","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.012_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.crohns.2010.11.002","article-title":"Development of testicular germ cell cancer following successful infliximab induction therapy for ulcerative colitis","volume":"5","author":"Wong","year":"2011","journal-title":"J\u00a0Crohns Colitis"},{"issue":"5, suppl","key":"10.1016\/j.mayocp.2014.08.012_bib18","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaad.2006.12.024","article-title":"Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies","volume":"56","author":"Fulchiero","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2014.08.012_bib19","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.12779","article-title":"Melanoma associated with tumour necrosis factor-\u03b1 inhibitors: a Research on Adverse Drug events And Reports (RADAR) project","volume":"170","author":"Nardone","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.mayocp.2014.08.012_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.mayocp.2014.08.012_bib21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.012_bib22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.mayocp.2014.08.012_bib23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrrheum.2013.134","article-title":"Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales","volume":"9","author":"Ioannidis","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.mayocp.2014.08.012_bib24","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.mayocp.2014.08.012_bib25","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.012_bib26","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ccr.2014.04.016","article-title":"Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry","volume":"25","author":"Feng","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.mayocp.2014.08.012_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1067\/mjd.2001.117725","article-title":"Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy","volume":"45","author":"Smith","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.mayocp.2014.08.012_bib28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.mayocp.2014.08.012_bib29","doi-asserted-by":"crossref","first-page":"387014","DOI":"10.1155\/2013\/387014","article-title":"DNA damage in inflammation-related carcinogenesis and cancer stem cells","volume":"2013","author":"Ohnishi","year":"2013","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"10.1016\/j.mayocp.2014.08.012_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40259-013-0022-9","article-title":"TNF inhibition for ophthalmic indications: current status and outlook","volume":"27","author":"Rifkin","year":"2013","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.mayocp.2014.08.012_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/archophthalmol.2009.151","article-title":"Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614007460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619614007460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T09:47:16Z","timestamp":1617616036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619614007460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0025619614007460"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2014.08.012","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}